Tough2gether Against DIPG/DMG (an operating subsidiary of Arms Wide Open Childhood Cancer Foundaiton) collaborates with the DIPG/DMG, brain cancer and pediatric cancer communities to bridge gaps in research funding, access to trials, patient support, relevant information to families and advocacy. Tough2gether sees itself as a crucial peace of the puzzle to bring research to the bedside and children with DIPG/DMG to better treatments. We also support childhood cancer famillies in the NE Kansas area. Tough2Gether Against DIPG/DMG began operating in 2021.

The cell and gene therapy community has a skills gap across all levels right up to the board positions. Companies struggle to recruit, retain, develop and promote employees for our rapidly growing and maturing industry. Diversity and inclusion at all career levels is vital if companies want to access untapped market space and retain their top talent and competitive advantage.

Women in Advanced Therapies is a specialist group for members of the Phacilitate network. It provides mentorship, networking and support for women working in advanced therapies. The goal is to build the foundations for a community to help recruit, retain, develop and promote women, creating leaders of tomorrow and encouraging new women to join the sector.

The Medicine Maker is a print and digital publication that explores the development and manufacture of small molecules, biologics, and advanced therapies draws on the talent, passion and experience of a wide range of professionals. Engaging content covers the entire spectrum of drug development, keeping all medicine makers up to date with the most pressing topics, trends and technologies driving the pharma industry forward.

Since its launch in 2014, The Medicine Maker has maintained an editorial focus on cell and gene therapies. In 2020, we launched a Cell and Gene newsletter dedicated to serving this distinct community within the pharmaceutical industry. You can subscribe to read more, here.

We experienced firsthand how cancer research is saving lives; however, children are still losing their lives every day because of limited treatment options for high-risk patients like Emily.

Children who have their cancer return are harder to treat because their cancer becomes resistant to standard therapies. Cutting edge treatments like CAR T-cell therapy are needed to help cure these children but funding is limited. Childhood cancer receives less than 4% of the National Cancer Institute budget for research. Many researchers rely on grants from non-profit organizations and private donors who are dedicated to raising funds for childhood cancer research.

Our focus will be on funding the most promising research such as the CAR T-cell therapy that Emily received and other immunotherapies. We will continue sharing Emily’s story to promote awareness and inspire others to take action and make a difference.